Market Update: Agilent Technologies Inc (NYSE:A) – Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma

[Business Wire] – Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced that the U.S. Food and Drug Administration has approved the expansion of the intended use of Dako PD-L1 IHC 28-8 pharmDx to include patients with melanoma. Read more on this. Agilent Technologies Inc. (A) , with a current value of $12.59B, started trading this morning at $37.40. During the trading session, A traded between $37.40 to $38.01 with its 52-week range being $33.12 to $43.59. A shares are currently priced at 19.99x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s 13.61x forward p/e ratio. And for income investors, the company pays shareholders $0.46 per share annually in dividends, yielding 1.21%. According to a consensus of 16 analysts, the earnings estimate of $0.43 per share would be $0.02 better than the year-ago quarter and a $0.04 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $1.90, which would be a $0.16 improvement when compared to the last year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $1.02 Billion. If realized, that would be a 0.97% decrease over the year-ago quarter. In terms of ratings, Deutsche Bank Initiated A at Hold (Jan 7, 2016). Previously, UBS Initiated A at to Neutral. The average price target for A shares by the analysts covering the stock is $46.04, which is 23.10% above where the stock opened this morning. See more in (NYSE:A) Similar Articles: Market Update: Agilent Technologies Inc (NYSE:A) – Agilent Technologies Names Michael Tang Senior Vice President, General Counsel and Secretary Company Update (NYSE:A): Dako, an Agilent Technologies Company, Announces FDA Approval of New Companion Diagnostic for Lung Cancer Market Update (NYSE:A): Agilent Technologies No Longer to Include Orders in Financial Reporting